| Literature DB >> 30923400 |
Michael A Mancano1, Morgan V Esordi1, Darshil D Patel1, Kristen J Milenki1.
Abstract
The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Administration's (FDA) MedWatch program (800-FDA-1088). If you have reported an interesting, preventable ADR to MedWatch, please consider sharing the account with our readers. E-mail Dr. Mancano at michael.mancano@temple.edu. Your report will be published anonymously unless otherwise requested. This feature is provided by the Institute for Safe Medication Practices (ISMP) in cooperation with the FDA's MedWatch program and Temple University School of Pharmacy. ISMP is an FDA MedWatch partner.Entities:
Year: 2019 PMID: 30923400 PMCID: PMC6431722 DOI: 10.1177/0018578718824449
Source DB: PubMed Journal: Hosp Pharm ISSN: 0018-5787